5001242026-11-04Disclosure25001242026-11-04Disclosure15001242026-11-04xbrli:sharesxbrli:pureiso4217:INR
Prohibition of Insider Trading
DR REDDY'S LABORATORIES LIMITED
General information about company
| Scrip Code | 500124 |
| NSE Symbol | DRREDDY |
| MSEI Symbol | NOTLISTED |
| Name of the Signatory | K RANDHIR SINGH |
| Designation of Signatory | Company Secretary and Compliance Officer |
| Place | HYDERABAD |
| Date of Filing | 04-11-2026 |
| ISIN Code | INE089A01031 |
| Disclosure under Regulation | Regulation 7 (2) |
| Revised Filing | No |
PIT Disclosure
| Sr. No. | Type of instrument | Description of type of instrument (applicable in case of other is selected) | Category of person | Name of the person | CIN / DIN | Securities held prior to acquisition / disposal | Securities acquired / disposed | Securities held post acquisition / disposal | Date of allotment advice / acquisition of shares / sale of shares specify | Mode of acquisition / disposal | Date of intimation to company | Type of contract | Contract specification | Buy | Sell | Exchange on which the trade was executed | Notes |
|---|
| No. of security | % of shareholding | No. of security | Value of security (in Rs.) | Transaction type | No. of security | % of shareholding | From date | To date | Notional value | No. of units (contracts × lot size) | Notional value | No. of units (contracts × lot size) |
|---|
|
| 1 | Any other instrument | ADRs | KMP | Erez Israeli | | 0 | 0.00% | 591270 | 794,666,880.00 | Buy | 591270 | 0.07% | 04-11-2026 | 04-11-2026 | ESOP | 04-11-2026 | | | | | | | NA | Textual Information(1) |
| 2 | Any other instrument | ADRs | KMP | Erez Israeli | | 591270 | 0.07% | 460276 | 617,564,567.00 | Sell | 130994 | 0.01% | 30-10-2026 | 03-11-2026 | Market Sale | 03-11-2026 | | | | | | | NA | Textual Information(2) |
Text Block
| Textual Information(1) | Mr Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs which were allotted by the Company on November 4, 2026. |
| Textual Information(2) | Mr Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs which were allotted by the Company on November 4, 2026. |